Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Theratechnologies Inc T.TH

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  THERF

Theratechnologies, Inc. is a biopharmaceutical company that specializes in therapeutic peptide products, with an emphasis on growth-hormone releasing factor, or GRF, peptides.
Price: $0.75 | Change: $-0.01 | %Change: -1.32%
Volume: 331,827 | Day High/Low: 0.83/0.70 | 52 Week High/Low: 0.76/0.325
View modes: 
0 stars

RE:RE:Up 36% on the week and still massively undervalued

Remember, that is EBITDA, not earnings. But yes, those numbers are still very exciting and what the company is guiding the market to believe is likely if the sales are achieved. Now, the corporate...read more
0 stars

RE:RE:RE:Up 36% on the week and still massively undervalued

No one knows the answer to this, of course, but it is a reasonable bet that it is higher than the 1,300 or so Serono peaked out at. I would not be surprised if the company could double that number...read more
0 stars

RE:RE:Up 36% on the week and still massively undervalued

Further price hikes will come each year, but massive ones are no longer likely. While the company needs to make a profit and the large price hikes over the last year year insure that, I don't expect...read more
0 stars

RE:RE:Up 36% on the week and still massively undervalued

using the company s presentation any patient over 1400 adds almost 36 000 cad dollrs to the bottom line ...I wonder what is- the attainable number of patients? 3000 ? 4000? 5000?  rate and reply
0 stars

RE:Up 36% on the week and still massively undervalued

Up 36% for the week but still down almost 90% from when Egrifta was launched. And when I run the numbers for 1300 patients I get from the current presentation : @ 1200 = US$15.9 million @ 1400 = US$21...read more
0 stars

RE:Up 36% on the week and still massively undervalued

"The 42% hike in the US price of Egrifta..." Once TH has penetrated the market and assured itself profitability what is preventing one more significant price hike if there are no other options for...read more
0 stars

Up 36% on the week and still massively undervalued

If you run the numbers the company ahs provided, it will be hard for TH not to earn $0.20 per share in 2016. And this only assumes that it manages to get back to the same level of sales as Serono...read more
0 stars

RE:RE:RE:canacord

A bit disturbing that the largest seller on the day of the upgrade by Canacord is a client of theirs! Just a coincidence I hope!!  rate and reply
0 stars

RE:RE:canacord

Not sure. But one or more of their clients have been selling quite a bit over the last few weeks.  rate and reply
0 stars

RE:canacord

How many shares did Canacord sell today?  rate and reply
0 stars

RE:canacord

Expect the target price to be raised next quarter IF they execute  rate and reply
0 stars

canacord

Raise TH from HOLD to BUY. Target $1.50  rate and reply
0 stars

RE:RE:RE:RE:RE:Great news this morning

This is very nice news but if it somehow takes your eye off the fact the company just upped its base case earnings potential by 70%+ yesterday, then you are missing the proverbial "forest for the...read more
0 stars

RE:RE:RE:RE:Great news this morning

Spain, Greece, Ireland? Any sales they get from Europe this year would be completely gravy and completely unexpected.  We'll see how it goes...  rate and reply
0 stars

RE:RE:RE:Great news this morning

Any incremental sales  is a positive even if the European sales will probably be less profitable than US sales I wonder why Italy is not included in the Agreement  rate and reply
0 stars

RE:RE:Great news this morning

AOP was willing to pay 150K euros (roughly $210K).  At least it is a step forward in Europe.  rate and reply
0 stars

RE:Great news this morning

Immediate sales thru the Named Patients Sales Program The level of sales under that program is not mentioned in the PR  rate and reply
0 stars

Great news this morning

Europe!!!  rate and reply
0 stars

RE:RE:THERF Just upped Earnings guidance for 2015 by 70%+!!!

If TH was a large company that many analysts were following, the news of the earnings upgrade would have been picked up right away and reflected in the share price in minutes. But it is a very small...read more
0 stars

RE:TH

Do you describe 800 patients, a number that is growing rapidly, as a handful? That is a weird way to define it. Also, why would the company dilute shareholders with a new offering when they have...read more